SEC Tracker
Get the app
INVA · XBRL financial data

Innoviva financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (INVA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers6786*771009092*89100108115*98120
Gross profit—year only608573—738376—7691
Research and development42*4344*48145*55
Selling, general and administrative2926*30282631*27262732*3235
Total operating expenses—year only34303035*32344137*3840
Operating income (loss)—year only26554343*41493539*3851
Interest expense46*6665*5543*55
Other income (expense)1(1)*(1)(1)(1)0*(1)(1)(0)(1)*(0)(0)
Income tax expense (benefit)4(0)*9(5)64*89831*48(25)
Earnings per share, basic USD per share1.26—0.58(0.55)0.02—(0.74)1.011.30—2.52(1.14)
Earnings per share, diluted USD per share0.98—0.46(0.55)0.02—(0.74)0.771.08—2.22(1.14)
Weighted average shares, basic millions of shares6564*63636363*63636975*7473
Weighted average shares, diluted millions of shares86106*85636387*638485—8573

Balance sheet

CSV

Fiscal quarters (INVA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents180194178217261305319398477551603570
Inventory414137373434414938393939
Prepaid and other current assets15221781321151719272524
Total current assets305344311358401554582652685728773753
Property and equipment, net000011002222
Right-of-use asset332332221111110
Goodwill181818181818181818181818
Total assets1,1881,2441,2681,2251,2321,3011,2541,3341,4291,6351,8371,703
Accounts payable471242556574
Total current liabilities3638302822423623524748503747
Long-term debt446446447447256256257257257258258258
Lease liability, non-current221221111111110
Retained earnings (accumulated deficit)(87)(25)11(23)(22)(2)(48)15105269456373
Total stockholders' equity—————691———1,1731,3421,233
Total liabilities and equity1,1881,2441,2681,2251,2321,3011,2541,3341,4291,6351,8371,703
Common shares outstanding (cover page) millions of shares646362636363636375747472

Cash flows

CSV

Fiscal quarters (INVA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Stock-based compensation1*1*12*2*2*22*2*3*35*
Net cash from operating activities44*33*3744*49*59*4944*50*55*3552*
Purchases of property and equipment0*0*00*0*0*00*1*0*00*
Net cash from investing activities(26)*(5)*(43)0*(5)*(15)*(35)33*18*24*37(55)*
Proceeds from issuing common stock0*0*00*0*1*01*0*1*02*
Share repurchases11*15*105*0*0*00*0*5*2031*
Net cash from financing activities(11)*(15)*(9)(5)*0*1*01*11*(4)*(20)(29)*
Net change in cash7*14*(15)39*44*44*1478*79*74*52(33)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Innoviva57012052*72.2M— 10-QJun 30, 2026
Ani Pharmaceuticals36026657*not reported— 10-QJun 30, 2026
Celldex Therapeutics470(57)*78.5M12.5 quarters 10-QJun 30, 2026
Travere Therapeutics12422598*96.0M— 10-QSep 30, 2026
Adaptive Biotechnologies17072(6.4)*159.6M53.8 quarters 10-QJun 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026
Mannkind53109(18)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger28859(34)*not reported12.1 quarters 10-QJun 30, 2026
Spyre Therapeutics83not reported(77)*95.0M15.7 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.